Abstract
BackgroundApproximately 50% of head and neck squamous cell carcinomas (HNSCC) recur after treatment with curative intent. Immune checkpoint inhibitors are treatment options for recurrent/metastatic HNSCC; however, less than 20% of...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have